Black Seed (Nigella Sativa) for Blood Sugar Regulation

Research suggests that Nigella sativa and its primary active compound thymoquinone show consistent evidence of blood sugar-lowering effects across a range of preclinical studies, including rat and mouse models of type 2 diabetes and insulin resistance, as well as cell culture experiments, with proposed mechanisms including activation of insulin signaling pathways, reduction of oxidative stress, support for pancreatic insulin-producing cells, and favorable shifts in gut microbiome composition. Multiple reviews of the literature, including one focused specifically on human randomized controlled trials, indicate that black seed demonstrates among the more consistent positive results for blood sugar regulation compared to other commonly studied herbs, and a 2025 review of human trial data characterizes the evidence as promising. However, the body of evidence has meaningful limitations: the majority of supportive studies are animal or cell-based research that cannot be directly applied to humans, and the one human randomized controlled trial included here — a small pilot study in healthy volunteers — found no significant effect on blood sugar or insulin measures at the dose and duration tested, suggesting that findings in diabetic animal models may not translate straightforwardly to human populations. Studies indicate that more rigorous, large-scale human trials are needed before firm conclusions can be drawn about the practical relevance of these effects for people managing blood sugar concerns.